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Background: Endometrial cancer is the most common gynaecological cancer and its incidence is predicted to escalate by
50–100% in 2025 with a parallel increase in associated mortality. Variations in the collection, processing and storage of
biospecimens can affect the generalisability of the scientific data. We aimed to harmonise the collection of biospecimens, clinical
data relevant to endometrial cancer and to develop standard operative procedures for the collection, processing and storage of
endometrial cancer biospecimens.
Methods: We designed research tools, which were evaluated and revised through three consensus rounds – to obtain local/
regional, national and European consensus. Modified final tools were disseminated to a panel (n¼ 40) representing all
stakeholders in endometrial cancer research for consensus generation.
Results: The final consensus demonstrated unanimous agreement with the minimal surgical and patient data collection tools.
A high level of agreement was also observed for the other remaining standard tools.
Conclusions: We here present the final versions of the tools, which are freely available and easily accessible to all endometrial
cancer researchers. We believe that these tools will facilitate rapid progress in endometrial cancer research, both in future
collaborations and in large-scale multicentre studies.
Endometrial cancer (EC) is the most common cancer of the female
genital tract in the developed world, and is the fourth most
common cancer in women after breast, lung and colorectal cancer
(Ferlay et al, 2015). In the United Kingdom in 2014, at least 6
women died of and 21 women were diagnosed with EC in the
United Kingdom every day, with 9022 new cases and 2166 deaths
reported that year (CRUK). The incidence rate of EC is increasing
rapidly and is estimated to increase by 50–100% by 2025
(Lindemann et al, 2010). This increase in incidence is alarming,
particularly due to the corresponding rise in mortality (CRUK).
Increased efforts into finding new prevention, diagnostic, prog-
nostic and therapeutic targets are therefore urgently required to
reduce the high mortality and morbidity rates associated with EC.
Traditionally, among others immunohistochemistry was used,
based on formalin-fixed paraffin-embedded tissue, allowing only
for the study of a limited number of proteins simultaneously.
Further cell lines and animal studies have been applied in EC
research; these however rarely give a perfect simulation of the
in vivo human environment. Therefore, biobanks, collecting a wide
range of different patient specimens, including for example fresh
frozen tissue, urine, blood or saliva, have a vital role in providing
valuable patient material for clinically relevant scientific discoveries
and also aid to the rapid translation of basic scientific findings to
clinical practice.
Through its nature, patient material stored in biobanks allows
for studying multiple aspects of EC. This is of paramount
importance with the emergence of novel technological platforms
in genomics, proteomics, epigenomics and metabolomics that can
be collectively and simultaneously applied to the same patient
samples to gain the maximum amount of information. Such an all-
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encompassing approach is expected to reduce considerably the
time taken for new basic scientific discoveries to reach patients as
new treatments as well as allowing the samples donated by patients
to be fully used.
The internal and external validity of the generated data depend
on their quality, which is clearly dependent on the use of stringent
standards in collecting the biospecimens and patient character-
istics. Variations associated with collecting, processing, storing
different biospecimens and the accompanying phenotypic and
demographic data make it extremely difficult to extrapolate or to
merge data from different studies (Tworoger and Hankinson, 2006;
Ransohoff and Gourlay, 2010). This lack of quality standards and
uniformity is recognised by the National Cancer Institute (NCI) as
a roadblock in cancer research (NCI Best Practices for Biospecimen
Resources, 2011). The irrevocable bias introduced by the
irregularities and dissimilarities in specimens and data collection
are well recognised by many and efforts are being made to
overcome this by several international organisations and agencies
(Morente et al, 2007; International Society for Biological and
Environmental Repositories, 2008; Yuille et al, 2008; Vaught and
Lockhart, 2012).
The NCI best practice guidance for biobanks (NCI Best
Practices for Biospecimen Resources, 2011, 2016), which
encourages optimisation of the resources available for cancer
research, broadly mentions a limited list of preanalytic variables
related to the donor or sample collection/processing. It has thereby
been effective in raising the overall awareness and quality of
research involving biospecimens.
Although this is an important start, many parameters and
variables of interest, including choice of biospecimens and clinical
data, are cancer-type-specific. Thus, universal biobanking stan-
dards are not necessarily applicable to every cancer type and
should be adapted to each specific disease. The importance of
cancer-specific harmonisation of biobanking standards is high-
lighted by the cancer genome atlas (Kandoth et al, 2013), which
now contains over 532 EC samples with RNA sequencing, copy
number variation, proteomic, mutation and microarray data.
However, the extremely limited clinical data accompanying most
of these samples and data sets severely affects the ability of
researchers to draw clinically applicable information.
Therefore, EC-specific standardisation of the collection of
biospecimens with distinctive and relevant accompanying clinical
data sets is a fundamental unmet need in improving future EC
research. This, we believe, will facilitate future large-scale
internationally collaborative research into EC, which could lead
to improved biomarker and target treatment discovery. Similar
harmonisation projects have already been successfully implemen-
ted for other gynaecological conditions such as endometriosis –
World Endometriosis Research Foundation Endometriosis Phe-
nome and Biobanking Harmonisation Project and Ovarian Cancer
Research Program (Wiegand et al, 2010; Heravi-Moussavi et al,
2012; Fassbender et al, 2014; Rahmioglu et al, 2014; Vitonis et al,
2014).
With this background, we initiated our study (Harmonisation of
biobAnking STandards in Endometrial caNcer research – HAS-
TEN) to achieve consensus among EC researchers; standardise the
collection, processing and storage of all relevant biospecimens; and
the accompanying clinical data for EC research through a joint
effort with patients, surgeons/physicians/pathologists and the
personnel of biobanks. We aimed to develop standards: standard
operative procedure tools with a minimum and standard data set
to be regularly updated and universally available for future
researchers in EC.
MATERIALS AND METHODS
The method used to design the final tools in HASTEN is
summarised in the flow diagram (Figure 1). We used a modified
Delphi system to analyse and confirm the final consensus.
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Figure 1. Flow chart illustrating our workflow in designing the EC research tools and the method of generating consensus (Endometrial cancer
(EC), European Network of Individualised Treatment in Endometrial Cancer (ENITEC), Endometrial Cancer Patient Data Collection Tool (ECPD),
Endometrial Cancer Surgical Data Collection Tool (ECSD), Endometrial Cancer Biospecimen Tool (ECBS), standard operating procedure for
collection, processing and storage of tissue and fluid for EC research (SOP-ECBS)).
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Generation of the initial tools
Literature search. We performed a systematic review of the
literature using the keywords ‘Endometrial Cancer’, ‘risk factors’,
‘age of presentation’, ‘parity’, ‘menopausal status’, ‘metformin’,
‘progestogens or Mirena’, ‘hormone replacement therapy’, ‘poly-
cystic ovary syndrome’, ‘tamoxifen’, ‘bowel cancer’, ‘colorectal
cancer’, ‘breast cancer’, ‘diabetes’, ‘hypertension’, ‘ethnicity’,
‘anthropometric assessment’, ‘smoking’, ‘standard operating pro-
cedure’ and ‘endometrium’, ‘blood or plasma or serum’, ‘saliva’,
‘urine’, ‘endometrial fluid’, ‘peritoneal fluid’, ‘biobank best
practices’ ‘histopathology markers’, ‘outcomes’, ‘biomarkers’,
‘Laboratory processing procedures of tissue, blood and body
fluids’, ‘biobanking standards’, ‘SOP’s for collection of tissue, fluids,
blood, saliva, urine’ in Scopus, Discover and PubMed databases.
The literature search was limited to studies published in the past 10
years. Out of 3464 papers identified in the initial search, 413 papers
were selected for further detailed scrutiny based on the following
inclusion criteria:
(1) Papers that investigated how the aforementioned factors affect
an individual’s risk of developing EC.
(2) Publications that proposed standard operating procedures
(SOPs) or best practices for the collection, storage and
processing of the different tissues or fluids.
(3) Papers in English language only.
(4) Papers available as full text via all available resources to the
authors (e.g., online resources or library facilities at Liverpool
Women’s Hospital (LWH), University of Liverpool, British
Medical Association or Royal College of Obstetricians and
Gynaecologists.
We further conducted manual searches for the relevant
manuscripts referenced in these selected papers and the relevant
guidelines from the large biorepositories.
FURTHER DEVELOPMENT OF THE TOOLS
First local consultation. The local team at Liverpool, comprising
of four members of surgical gynaecological oncology team, four
Macmillan clinical cancer nurse specialists, two clinical academics
with an interest in EC research, two pathologists, two biobank staff
members and a medical student, developed the three forms
(patient data collection tool, surgical data collection tool, biospeci-
men form) and a standard operative procedure. These forms and
the SOP were based on: (a) the information gathered in the
literature search; (b) by considering the forms that were already in
use in LWH/University of Liverpool biobank to collect biospeci-
mens and data in EC research studies. Liverpool Women’s Hospital
is a tertiary referral regional cancer centre for gynaecological
cancers, and is part of the Cheshire and Merseyside strategic
clinical networks, which serves a population of 2.4 million. The
age-standardised incidence rate of EC in the Merseyside and
Cheshire cancer network is 18.3 per 100 000 female members of the
population (NCIN, 2013; Gynae Clinical Network Constitution,
2014–2015). (c) Standard operating procedures developed by the
National Institutes of Health, Human Endometrial Tissue and
DNA Bank for the collection, transport and storage of human
endometrial tissue and blood samples of women undergoing
endometrial biopsy or hysterectomy for non-malignant indications
(Sheldon et al, 2011). (d) Sample handling and storage protocol
published by the UK biobank to collect urine and blood samples
(Elliott et al, 2008). UK biobank is a major national and
international health resource, which was established by Wellcome
trust, Medical Research Council, Department of Health, Scottish
Government and The Northwest Regional Development Agency.
The main aim of this was to improve prevention, diagnosis and
treatment of many illnesses such as cancer, heart disease, stroke,
diabetes, arthritis, osteoporosis and dementia.
The forms were revised and amended based on local
consultation.
Second regional/national consultation. The modified versions of
the three forms and the SOP mentioned above were disseminated
among three regional and eight national research centres involved
in EC research in the United Kingdom and forms were revised
integrating their feedback and as a result, two different tools, a
minimal and a standard tool were developed. This pragmatic and
inclusive approach provides guidance for collecting either a
minimal or the ideal ‘standard’ data set considering the available
resources.
Third European consultation. The modified forms were then
circulated to all researchers adhering to the European Network of
Individualised Treatment in Endometrial Cancer (ENITEC) and
were further revised according to feedback received. The revised
tools were presented at the annual ENITEC face-to-face meeting in
June 2016, where the minimal form was unanimously approved by
all 47 attendees. Some further modifications were suggested for the
standard tool, which was revised accordingly and the revised forms
were repopulated to all participated in the consultations rounds
1–3 to obtain their final approval.
Consensus generation. A modified Delphi system was used to
generate consensus regarding the final adapted tools. For this, the
forms were disseminated to a group of selected panel members of
representing all stakeholders included in all previous rounds,
including patients, gynaecological oncologists, researchers, pathol-
ogists and biobank staff, randomly selected from the participants of
the consultation (n¼ 40) to evaluate and score the tools using a
scoring sheet recording their agreement.
Statistical analysis. The consensus was quantified using a
modified Delphi technique and we have reported the median with
an interquartile range and also percentages for each category of the
Likert scale. A nine-point Likert scale was used, except for the
patient data tool where the scale was reduced to five points to
reduce complexity for patients.
RESULTS
Final tools
ECPD collection tool. A patient-friendly data collection tool (EC
patient data (ECPD)) was devised to capture many important
demographic variables that are directly relevant to EC research that
can only be accurately recalled by the patient herself. For example,
the available literature suggests that420 kg of adult weight gain to
be independently associated with increased risk of EC
(Friedenreich et al, 2007) and this information is unlikely to be
obtained easily other than directly from the patient. Many other
risk factors for EC such as the age of presentation, the
postmenopausal status, polycystic ovarian disease (Fearnley et al,
2010), nulliparity (Schonfeld et al, 2013), early age of menarche
(Gong et al, 2015), family history of hereditary lynch syndrome-
related cancers (Boilesen et al, 2008), past history of lynch
syndrome-related cancers, medical conditions such diabetes
(Friberg et al, 2007), previous use of tamoxifen (Bergman et al,
2000), hormone replacement therapy use (Beral et al, 2005) and
exercise habits have been included in the tool. Some other factors
with inconclusive links to EC at present such as smoking
(Lindemann et al, 2008) were also included in anticipation of
their confirmation in appropriate future studies. Table 1 and
Figure 2 illustrate the outcome of the final round of consensus.
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Score for each question in ECPD was obtained using the Likert
scale, which assesses the acceptability and usability (n¼ 10).
Among the panel members, only 2% were undecided on the clarity
of the questions in social history section, and overall, 98% patients
agreed that the tool was easy to use (Supplementary Figure S1).
ECSD collection tool. The EC surgical data (ECSD) tool included
salient demographic, histological and pre/postoperative features.
Demographic features such as body mass index (BMI) were
included. Body mass index instead of waist-to-hip ratio or waist
circumference was chosen because of its universal use and
reproducibility. Although all anthropometric assessments (BMI,
waist-to-hip ratio, waist and hip circumferences) are found to be
strongly associated with increased risk of EC (Friedenreich et al,
2007), accurate data on waist-to-hip ratio or waist circumferences
require additional effort using the same reference points by health-
care team and thus accurate data collection is unlikely to be
universally feasible. In a recent study (Painter et al, 2016), BMI was
Table 1. Outcome of the final round of consensus for ECPD Tool using 5-point Likert scale
Percentages of responses (%)
Statements in the score sheet for patients
Score,
median (IQR)
Strongly
agree Agree Undecided Disagree
Strongly
disagree
The information asked in personal history is easy to fill 1 (1–2) 60 40 0 0 0
The questions in medical history section are easy to
understand and fill
1 (1–2) 60 40 0 0 0
The questions in past history are easy to understand and fill 1 (1–2) 60 40 0 0 0
The questions in social history section are easy to understand
and fill
1 (1–2) 60 30 10 0 0
Overall, the form is easy to understand and does not take
much time to fill it
1.5 (1–2) 50 50 0 0 0
Abbreviations: ECPD¼Endometrial Cancer Patient Data; IQR¼ interquartile range. IQR, five-point Likert scale: Strongly agree, Agree, Undecided, Disagree and Strongly disagree; n¼ 10.
Statistical analysis of ECPD tool
(median with interquartile range)
Statistical analysis of ECSD tool
(median with interquartile range)
Statistical analysis of ECBS tool
(median with interquartile range)
Statistical analysis of SOP-ECBS tool
(median with interquartile range)
Q1
A D
B
C
Q2
Q3
Qu
es
tio
ns
Q4
Q5
Q1
Q2
Q3
Qu
es
tio
ns
Q4
Q5
Q6
Q7
Q8
Q1
Q2
Q3
Qu
es
tio
ns
Qu
es
tio
ns
Q4
Q1
Q2
Q3
Q4
Q5
Q6
Q7
Q8
Q9
Q10
Q11
Q12
Q13
Q14
Q15
Q16
0 1 2
Likert scale
3 4 5
0 1 2
Likert scale
3 4 5 6 7 8
0 1 2
Likert scale
3 4 5 6 7 8
9
9
0 1 2
Likert scale
3 4 5 6 7 8 9
Figure 2. Statistical analysis of Endometrial Cancer Patient Data Collection Tool (ECPD), Endometrial Cancer Surgical Data Collection Tool
(ECSD), Endometrial Cancer Biospecimen Tool (ECBS) and standard operating procedure for collection, processing and storage of tissue and
fluid for EC research (SOP-ECBS) tools.
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found to be a causal factor and was associated with EC compared
with waist-to-hip ratio. The preoperative imaging details are
helpful to assess the spread locally and to rule out distant
metastases. Discordance between endometrial biopsy and
final histology results has been shown to be associated with poorer
survival outcome (Werner et al, 2013); hence, preoperative biopsy
results are important. Staging details including operative
findings and final histopathologic details after surgery are
important when correlating with outcomes. Immunohistochemical
biomarkers can be used to distinguish ECs from ovarian or cervical
or other malignancies, but importantly also as prognostic
biomarkers that are associated with clinical outcome (Li et al,
2013; Kamal et al, 2016). Information when collected in a standard
way together with biosamples will naturally increase the internal
and external validity of the generated data. The patient data
collection, including follow-up and accurate documentation of
cause of demise, should be updated regularly until the completion
of standard follow-up period (either 3 years (minimum) or 5 years,
depending on local practice). The form is arranged into three
sections:
(1) Surgical data: Completed at the time of sample collection.
(2) Histopathology details: Completed after final staging and
treatment.
(3) Outcome data: Documented during follow-up and finally at
the end of follow-up
The results of final consensus are as shown in Table 2 and
Figure 2, wherein we have calculated the median with an
interquartile range. There was a high level of agreement among
the panellists for all sections, except that a number of the
respondents considered sections on the history, antecedent biopsy
details and sample collection details to be not relevant. Overall,
96.25% of panel members agreed on different aspects of the tool
(Supplementary Figure S1).
EC Biospecimen tool. Variations in the collection methods and
biobanking conditions (processing and storage) may alter the
molecular composition, expression and stability of biomarker
profile (Zander et al, 2014); thus, consistency and strict adherence
to standard operating procedures is vital (Moore et al, 2011).
Therefore, biobank staff with applied experience and knowledge on
clinical biobanking participated in designing, revising and obtain-
ing final consensus on the biospecimen form. Only few
respondents felt that the tissue processing (both uterine and
extrauterine) section of the form was difficult to understand, while
all respondents agreed on the relevance and clarity of all other
sections. Overall, there was a 94% level of agreement on the
different aspects of this tool. The detailed results were as shown in
Table 3, Figure 2 and Supplementary Figure S1.
Standard operating procedure for collection, processing and
storage of tissue and fluid for EC research. Different tissue types
(both uterine and extrauterine) and body fluid types are studied in
EC research. The routine investigations of these biospecimens may
involve extraction of protein, RNA and DNA to be evaluated using
a variety of techniques such as proteomics, genomics and
metabolomics. The final SOP was designed amalgamating a
number of available separate, detailed methodological protocols
(e.g., for centrifugation, filtration, addition of preservatives, as well
as storage temperatures). Availability of such information from a
biobank will allow the scientists to accurately interpret their data,
for example, to examine the metabolic profile of samples such as
blood, tissue, endometrial fluid or aspirate and detect disease-
specific changes with confidence, especially in multicentre studies
(Assfalg et al, 2008; Bernini et al, 2009). Studies examining
hormones are of major relevance to the endometrium, and in
addition to more traditional samples such as blood, some have
studied noninvasive specimens including saliva and urine
(Shirtcliff et al, 2001). Noninvasive tests are of a particular interest
in clinical research and future work is expected to focus more on
them.
The outcome details of the final round of consensus regarding
the standard operating procedure for collection, processing and
storage of tissue and fluid for EC research (SOP-ECBS) are as
presented in Table 4 and Figure 2. There was a general agreement
Table 2. Outcome of the final round of consensus for ECSD Tool using nine-point Likert scale
Percentages of responses (%)
Questions in the
score sheet for
gynaeoncologists
Score,
median
(IQR)
Strongly
agree Agree
Moderately
agree
Mildly
agree Undecided
Mildly
disagree
Moderately
disagree Disagree
Strongly
disagree
Is the general
information about
patient relevant?
2 (1.75–2) 20 80 0 0 0 0 0 0 0
Is the section on history
relevant?
2 (2–3) 10 60 20 0 0 0 0 10 0
Are the Imaging details
relevant and sufficient?
2 (2–4) 10 80 0 30 0 0 0 0 0
Are Antecedent biopsy
details relevant?
2 (2–2) 10 80 0 0 0 0 0 0 10
Is the Operative findings
section relevant?
2 (1.75–2) 20 80 0 0 0 0 0 0 0
Is the Histopathology
type details section
relevant and sufficient?
2 (1.75–2.25) 20 60 10 10 0 0 0 0 0
Is the Sample collection
details section easy to
complete?
2 (1–2) 40 50 0 0 0 0 0 0 10
Are Outcome details
relevant?
2 (1.75–2.25) 20 60 10 10 0 0 0 0 0
Abbreviations: ECSD¼Endometrial Cancer Surgical Data; IQR¼ interquartile range. IQR, nine-point Likert scale: Strongly agree, Agree, Moderately agree, Mildly agree, Undecided, Mildly
disagree, Disagree and Strongly disagree; n¼ 10.
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on the user-friendliness and relevance of the tool. Few panellists
responded that tissue and blood collection details could be
modified further for clarity. Overall, 83.75% of panellists agreed,
8.75% were undecided and 7.5% disagreed with different sections
of this tool.
DISCUSSION
We have developed evidence-based standard data collection forms
ECPD, ECSD (minimal), ECSD (Standard) and an SOP-ECBS with
inclusive participation and approval of all stakeholders in EC
cancer biobanking. The final tools were approved by a large
multidisciplinary team of reviewers and after reaching consensus
(see Supplementary Figure S1), they are published as
Supplementary Information with this open access manuscript.
They will therefore be freely available to all EC researchers
internationally. These tools provide a means by which to reduce
confounding factors in the collected data and facilitate larger
multicentre studies.
Our choice of the exact information to collect was based on
critical appraisal of the best available evidence. Where no published
evidence was available, consultation of the experts’ opinion and the
SOPs of the larger biobanks were considered. The centrifugation
speed in processing blood was one such example.
We have used a modified Delphi technique, with multiple
alterations from the standard technique, including multiple rounds
of feedback, which allows the same panel members to reassess or
reconsider initial judgment, participant anonymity, controlled
feedback and statistical analysis to interpret data between
the rounds. Similar variations to original Delphi system, for
example, restricting the ability of the experts to respond to the
original question and alterations in the expert groups, as
well as changing the end point, have been used previously
(Thompson, 2009).
Repeated use of a homogenous panel was unjustifiable for our
research aims for the following reasons. Our endeavour was to
generate separate forms for diverse end points, for example, patient
data collection, surgical data collection, tissue processing informa-
tion and the standard operative procedures. These obviously
required panel members of diverse backgrounds, with different
fields of expertise and therefore our panellists were not a
homogenous group.
The main deviation from the classic technique was the number
of consultation rounds and the end point. Our first two rounds
were descriptive to generate opinions and ideas from different
expert panels. We included their feedback to generate the finalised
forms and SOP. In the final round of the consensus, we distributed
a score sheet to each of the panellists along with the forms to
evaluate their agreement with the final tools. Our final panel
included stakeholders representing those involved in all previous
panels. The high percentage of agreement observed with the
statistical analysis of data obtained from the third and final round
precluded the need for any further consensus rounds.
As more detailed, standardised surgical data collection will allow
a comprehensive assessment of the relationship between the
surgical phenotypical data with the outcomes of treatments, we
strongly advise the use of the standard rather than the minimal
ECSD tool. However, if the collection or quality of the large set of
data or specimens cannot be guaranteed, the minimal set should be
employed. We plan to regularly update these tools in the future
through information obtained by feedback and review of future
literature, initially on a yearly basis and 5 yearly thereafter. Future
considerations in the context of our initiatives include creating an
internationally funded web-based central database system allowing
voluntary deposition of the information on all biospecimens
collected by EC researchers worldwide, which will be easily
accessible to all. This approach, we believe, will reduce costs and
time spent by individual units while increasing the credibility of the
data generated and will offer a transparent, common platform for
newer collaborations.
‘Molecular Pathological Epidemiology’ (MPE) integrates pathol-
ogy and epidemiology to understand the interrelationships
between exogenous and endogenous factors that affect carcinogen-
esis, progression and response to treatment. It is a constantly
evolving field in cancer research (Ogino and Stampfer, 2010).
Statistical methods have also been developed to consider both
molecular pathology and epidemiology to ensure novel discoveries
with high clinical impact. However, the generation of such high-
impact MPE studies are impeded by similar challenges including
Table 3. Outcome of the final round of consensus for ECBS Tool using nine-point Likert scale
Percentages of responses (%)
Questions in the
score sheet for
biobank staff
Score
Median
(IQR)
Strongly
agree Agree
Moderately
agree
Mildly
agree Undecided
Mildly
disagree
Moderately
disagree Disagree
Strongly
disagree
Sample ID–Is this
relevant?
1 (1–1) 90 10 0 0 0 0 0 0 0
Methods of tissue
processing
(Endometrium)–Is this
section easy to
understand?
2 (1–3.25) 40 30 10 10 0 0 0 10 0
Methods of tissue
processing (Extra uterine
tissue)–Is this section
easy to understand?
2 (1–3.25) 40 30 10 10 0 0 0 10 0
Methods of fluid
processing
(Endometrial/Peritoneal/
Blood/Saliva/Urine)–Is
this section easy to
understand?
2.5 (2–4) 10 40 10 40 0 0 0 0 0
Abbreviations: ECBS¼Endometrial Cancer Biospecimen; IQR¼ interquartile range. IQR, nine-point Likert scale: Strongly agree, Agree, Moderately agree, Mildly agree, Undecided, Mildly
disagree, Disagree and Strongly disagree; n¼ 10
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selection and recall bias, measurement errors and misclassification
comparable to the traditional molecular biological studies (Hughes
et al, 2012; Campbell et al, 2017). Variability in tissue retrieval rate
and sample sizes leads to random and non-random selection bias,
resulting in large variation of an effect estimate with wide
confidence intervals and publication bias (Ogino et al, 2011,
2016). The use of our tools by EC biobanks will provide means
with which to streamline the collection of a large amount of
standardised quality assured material from well-phenotyped
patients. This will in turn facilitate adequately powered studies,
giving high clinical impact while also facilitating high-quality
research that is attainable within an acceptable timescale.
Table 4. Outcome of the final round of consensus for SOP-ECBS Tool using nine-point Likert scale
Percentages of responses (%)
Questions in the score
sheet for pathologists
Score
Median
(IQR)
Strongly
agree Agree
Moderately
agree
Mildly
agree Undecided
Mildly
disagree
Moderately
disagree Disagree
Strongly
disagree
Is section: Processing and
storage materials, relevant
and easy to understand?
2 (2–3.75) 10 50 20 0 0 20 0 0 0
Is section: Collection–Tissue,
relevant and easy to
understand?
2.5 (2–5.5) 10 40 10 10 10 0 20 0 0
Is section: Collection–Blood,
relevant and easy to
understand?
4.5 (2–7) 10 30 0 10 10 10 30 0 0
Is section: Collection – Urine,
relevant and easy to
understand?
2 (2–2) 10 80 10 0 0 0 0 0 0
Is section: Collection –
Saliva, relevant and easy to
understand?
2 (2–2.5) 10 70 0 10 10 0 0 0 0
Is section: Collection –
Peritoneal fluid, relevant and
easy to understand?
2 (2–2.75) 0 80 0 0 20 0 0 0 0
Is section: Collection –
Endometrial fluid/uterine
aspirates, relevant and easy
to understand?
2 (2–2.75) 0 80 0 0 20 0 0 0 0
Is section: Sample
processing – Tissue, relevant
and easy to understand?
2 (2–3.25) 0 70 10 10 10 0 0 0 0
Is section: Sample
processing – Blood, relevant
and easy to understand?
2 (2–4) 0 60 10 20 10 0 0 0 0
Is section: Sample
processing – Urine, relevant
and easy to understand?
2 (2–3) 0 70 20 0 0 10 0 0 0
Is section: Sample
processing – Saliva, relevant
and easy to understand?
2 (2–4.25) 0 60 10 10 10 10 0 0 0
Is section: Sample
processing – Peritoneal fluid,
relevant and easy to
understand?
2 (2–2) 10 80 0 0 10 0 0 0 0
Is section: Sample
processing – Endometrial
fluid/uterine aspirates,
relevant and easy to
understand?
2 (2–2) 10 80 0 0 10 0 0 0 0
Is section: Storage and data
recording, relevant and easy
to understand?
2 (2–2.25) 10 70 10 0 0 10 0 0 0
Is section: Freezer check,
relevant and easy to
understand?
2 (2–4.25) 0 60 10 10 10 10 0 0 0
Is section: Checklist, relevant
and easy to understand?
2.5 (2–4) 0 50 10 30 10 0 0 0 0
Abbreviations: IQR¼ interquartile range; SOP-ECBS¼ standard operating procedure for collection, processing and storage of tissue and fluid for EC research. IQR, nine-point Likert scale:
Strongly agree, Agree, Moderately agree, Mildly agree, Undecided, Mildly disagree, Disagree and Strongly disagree; n¼ 10.
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